_256_384.jpg)
Drug Approval | April 27, 2026
Cipla wins USFDA nod for first generic of Ventolin HFA strengthening respiratory push
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
The deal signals a clear push to expand access to care in underserved regions
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing
With a PhD in Biochemistry and an executive MBA, she brings nearly two decades of experience in the in vitro diagnostics (IVD) sector
Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market
Neuland Laboratories reported an uptick in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages
C. P. Radhakrishnan urged graduates to uphold ethical standards and maintain a commitment to patient care
Targets high-growth eye care expansion push
Subscribe To Our Newsletter & Stay Updated
